Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06810778 · ClinicalTrials.gov registry record · Phase 1
Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
A Phase 1 study of T-cell-prolymphocytic Leukemia and Cutaneous T-Cell Lymphoma Refractory, sponsored by Jonsson Comprehensive Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06810778 is a Phase 1 study of T-cell-prolymphocytic Leukemia and Cutaneous T-Cell Lymphoma Refractory that is actively recruiting participants, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 12 participants, below the 180-participant average among 7 other T-cell-prolymphocytic Leukemia trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06810778, a Phase 1 study of T-cell-prolymphocytic Leukemia and Cutaneous T-Cell Lymphoma Refractory, is actively recruiting participants, sponsored by Jonsson Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, phase I/II study of duvelisib in combination with Venetoclax for patients with relapsed/refractory NHL. Duvelisib is an FDA approved, marketed product used to treat certain patients with leukemia and lymphoma and Venetoclax, which is approved for treatment of certain patients with acute myeloid leukemia. The combination of these two drugs is experimental. Experimental means that it is not approved by the United States Food and Drug Administration (FDA). The researchers want to find out how safe it is to combine these drugs and how well this combination can work for your cancer.
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Duvelisib
Study Locations (1)
California
- David Geffen School of Medicine at the University of California at Los Angeles - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-05-02 |
| Est. Completion | 2031-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06810778
The ClinicalTrials.gov registry entry for NCT06810778 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 180-participant average among 7 other T-cell-prolymphocytic Leukemia trials with a reported enrollment target (93% lower). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with T-cell-prolymphocytic Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Venetoclax is the first listed.
NCT06810778 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06810778 about?
NCT06810778 is a clinical study titled "Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)". This is an open-label, phase I/II study of duvelisib in combination with Venetoclax for patients with relapsed/refractory NHL. Duvelisib is an FDA approved, marketed product used to treat certain patients with leukemia and lymphoma and Venetoclax, which is approved for treatment of certain patients ...
What is the current status of trial NCT06810778?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2025-05-02. Estimated completion is 2031-06-01.
What conditions does trial NCT06810778 study?
This clinical trial studies the following conditions: T-cell-prolymphocytic Leukemia, Cutaneous T-Cell Lymphoma Refractory.
What interventions are being tested in trial NCT06810778?
The interventions under investigation include: Venetoclax (DRUG), Duvelisib (DRUG).
Who is sponsoring clinical trial NCT06810778?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06810778 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for T-cell-prolymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
RECRUITING · Phase 1
-
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
RECRUITING · Phase 1
-
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
ACTIVE NOT RECRUITING · Phase 1
-
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
A Registry for People With T-cell Lymphoma
RECRUITING
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
Explore more on PlainTrial
T-cell-prolymphocytic Leukemia
All registered trials for this condition
Cutaneous T-Cell Lymphoma Refractory
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.